{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:49:38Z","timestamp":1779306578651,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.bmcl.2022.128591","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T11:47:51Z","timestamp":1643629671000},"page":"128591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["3,5-Bis(trifluoromethyl)phenylsulfonamides, a novel pancreatic cancer active lead. Investigation of the terminal aromatic moiety"],"prefix":"10.1016","volume":"61","author":[{"given":"Jufeng","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joey I.","family":"Ambrus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia C.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Cossar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennette A.","family":"Sakoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Scarlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"McCluskey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128591_b0005","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2217\/fon-2016-0010","article-title":"Pancreatic cancer: yesterday, today and tomorrow","volume":"12","author":"Ansari","year":"2016","journal-title":"Future Oncol."},{"key":"10.1016\/j.bmcl.2022.128591_b0010","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.lpm.2019.02.030","article-title":"Epidemiology and burden of pancreatic cancer","volume":"48","author":"Maisonneuve","year":"2019","journal-title":"La Press M\u00e9dicale."},{"key":"10.1016\/j.bmcl.2022.128591_b0015","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J Gastroentero."},{"key":"10.1016\/j.bmcl.2022.128591_b0020","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00595-020-02028-0","article-title":"Pancreatic cancer treatment: better, but a long way to go","volume":"50","author":"Torphy","year":"2020","journal-title":"Surg Today."},{"key":"10.1016\/j.bmcl.2022.128591_b0025","first-page":"603","article-title":"NCCN Guidelines Updates: Pancreatic Cancer","volume":"17","author":"Tempero","year":"2019","journal-title":"J National Compr Cancer Netw Jnccn."},{"key":"10.1016\/j.bmcl.2022.128591_b0030","doi-asserted-by":"crossref","first-page":"826","DOI":"10.31128\/AJGP-06-19-4957","article-title":"Pancreatic cancer: An update on diagnosis and management, Australian","volume":"48","author":"Loveday","year":"2019","journal-title":"J Gen Pract."},{"key":"10.1016\/j.bmcl.2022.128591_b0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.bmcl.2022.128591_b0040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.canlet.2015.11.048","article-title":"The lymphatic system and pancreatic cancer","volume":"381","author":"Fink","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bmcl.2022.128591_b0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2016.12.035","article-title":"Pancreatic cancer: Stroma and its current and emerging targeted therapies","volume":"391","author":"Kota","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bmcl.2022.128591_b0050","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semradonc.2016.05.002","article-title":"Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer","volume":"26","author":"Chadha","year":"2016","journal-title":"Semin Radiat Oncol."},{"key":"10.1016\/j.bmcl.2022.128591_b0055","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1186\/s12885-019-6284-y","article-title":"MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators","volume":"19","author":"Daoud","year":"2019","journal-title":"Bmc Cancer."},{"key":"10.1016\/j.bmcl.2022.128591_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07853890.2018.1453168","article-title":"Pancreatic cancer subtypes: a roadmap for precision medicine","volume":"50","author":"Torres","year":"2018","journal-title":"Ann Med."},{"key":"10.1016\/j.bmcl.2022.128591_b0065","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.21873\/anticanres.13026","article-title":"Targeted Therapies for Pancreatic Cancer and Hurdles Ahead","volume":"38","author":"Aslan","year":"2018","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bmcl.2022.128591_b0070","doi-asserted-by":"crossref","first-page":"102016","DOI":"10.1016\/j.ctrv.2020.102016","article-title":"Immunotherapy for pancreatic cancer: A 2020 update","volume":"86","author":"Schizas","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bmcl.2022.128591_b0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41571-019-0281-6","article-title":"From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer","volume":"17","author":"Nevala-Plagemann","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.bmcl.2022.128591_b0080","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1083\/jcb.108.2.569","article-title":"Isolation of a new member of the S100 protein family: amino acid sequence, tissue, and subcellular distribution","volume":"108","author":"Glenney","year":"1989","journal-title":"J Cell Biol."},{"key":"10.1016\/j.bmcl.2022.128591_b0085","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.drudis.2017.01.012","article-title":"Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer","volume":"22","author":"Totti","year":"2017","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.bmcl.2022.128591_b0090","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jmb.2008.03.019","article-title":"Crystal Structure of Ca2+-Free S100A2 at 1.6-\u00c5 Resolution","volume":"378","author":"Koch","year":"2008","journal-title":"J Mol Biol."},{"key":"10.1016\/j.bmcl.2022.128591_b0095","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.bbrc.2004.07.096","article-title":"S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature)","volume":"322","author":"Marenholz","year":"2004","journal-title":"Biochem Bioph Res Co."},{"key":"10.1016\/j.bmcl.2022.128591_b0100","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1523-1747.2000.00078.x","volume":"115","author":"Deshpande","year":"2000","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.bmcl.2022.128591_b0105","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7","article-title":"Expression pattern of S100 calcium-binding proteins in human tumors","volume":"68","author":"Ilg","year":"1996","journal-title":"Int J Cancer."},{"key":"10.1016\/j.bmcl.2022.128591_b0110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrc3893","article-title":"S100 proteins in cancer","volume":"15","author":"Bresnick","year":"2015","journal-title":"Nat Rev Cancer."},{"key":"10.1016\/j.bmcl.2022.128591_b0115","first-page":"291","article-title":"Calcium-Binding Proteins of the EF-Hand Superfamily, From Basics to Medical Applications","volume":"2019","author":"Wilder","year":"1929","journal-title":"Methods Mol Biol."},{"key":"10.1016\/j.bmcl.2022.128591_b0120","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s12551-018-0471-y","article-title":"S100 proteins as therapeutic targets","volume":"10","author":"Bresnick","year":"2018","journal-title":"Biophys Rev."},{"key":"10.1016\/j.bmcl.2022.128591_b0125","doi-asserted-by":"crossref","first-page":"6628","DOI":"10.1021\/bi5005552","article-title":"Covalent Small Molecule Inhibitors of Ca2+-Bound S100B","volume":"53","author":"Cavalier","year":"2014","journal-title":"Biochemistry-Us."},{"key":"10.1016\/j.bmcl.2022.128591_b0130","doi-asserted-by":"crossref","first-page":"112621","DOI":"10.1016\/j.ejmech.2020.112621","article-title":"Discovery of novel small molecule inhibitors of S100P with in vitro anti-metastatic effects on pancreatic cancer cells","volume":"203","author":"Camara","year":"2020","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128591_b0135","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202000950","article-title":"Novel cytotoxic 1,2,3-triazoles as potential new leads targeting the S100A2-p53complex","author":"Sun","year":"2021","journal-title":"ChemMedChem."},{"key":"10.1016\/j.bmcl.2022.128591_b0140","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202000949","article-title":"Targeting the S100A2-p53 interactions with a series of novel 3,5-bistrifluoromethylbenzene sulfonamides: Synthesis and cytotoxicity","author":"Sun","year":"2021","journal-title":"ChemMedChem."},{"key":"10.1016\/j.bmcl.2022.128591_b0145","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.gastro.2009.04.009","article-title":"Expression of S100A2 Calcium-Binding Protein Predicts Response to Pancreatectomy for Pancreatic Cancer","volume":"137","author":"Biankin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bmcl.2022.128591_b0150","doi-asserted-by":"crossref","first-page":"29186","DOI":"10.1074\/jbc.M505000200","article-title":"The Calcium-binding Protein S100A2 Interacts with p53 and Modulates Its Transcriptional Activity*","volume":"280","author":"Mueller","year":"2005","journal-title":"J Biol Chem."},{"key":"10.1016\/j.bmcl.2022.128591_b0155","first-page":"2706","article-title":"The role of S100 proteins and their receptor RAGE in pancreatic cancer","volume":"2015","author":"Leclerc","year":"1852","journal-title":"Biochimica Et Biophysica Acta Bba - Mol Basis Dis."},{"key":"10.1016\/j.bmcl.2022.128591_b0160","doi-asserted-by":"crossref","first-page":"13804","DOI":"10.1074\/jbc.M901351200","article-title":"Modulation of the Oligomerization State of p53 by Differential Binding of Proteins of the S100 Family to p53 Monomers and Tetramers \u2666","volume":"284","author":"van Dieck","year":"2009","journal-title":"J Biol Chem."},{"key":"10.1016\/j.bmcl.2022.128591_b0165","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jmb.2009.10.002","article-title":"Posttranslational Modifications Affect the Interaction of S100 Proteins with Tumor Suppressor p53","volume":"394","author":"van Dieck","year":"2009","journal-title":"J Mol Biol."},{"key":"10.1016\/j.bmcl.2022.128591_b0170","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0014-5793(99)00135-0","article-title":"Transcriptional activation of the human S100A2 promoter by wild-type p53","volume":"445","author":"Tan","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bmcl.2022.128591_b0175","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Initiative","year":"2016","journal-title":"Nature."},{"key":"10.1016\/j.bmcl.2022.128591_b0180","doi-asserted-by":"crossref","unstructured":"S.B. Dreyer, M. Pinese, N.B. Jamieson, C.J. Scarlett, E.K. Colvin, M. Pajic, A.L. Johns, J.L. Humphris, J. Wu, M.J. Cowley, A. Chou, A.M. Nagrial, L. Chantrill, V.T. Chin, M.D. Jones, K. Moran-Jones, C.R. Carter, E.J. Dickson, J.S. Samra, N.D. Merrett, A.J. Gill, J.G. Kench, F. Duthie, D.K. Miller, S. Cooke, D. Aust, T. Kn\u00f6sel, P. R\u00fcmmele, R. Gr\u00fctzmann, C. Pilarsky, N.Q. Nguyen, E.A. Musgrove, P.J. Bailey, C.J. McKay, A.V. Biankin, D.K. Chang, A.P.C.G. Initiative, G.P.O. Laboratory, Precision Oncology in Surgery, Ann Surg. Publish Ahead of Print (2018) NA; https:\/\/doi.org\/10.1097\/sla.0000000000003143.","DOI":"10.1097\/SLA.0000000000003143"},{"key":"10.1016\/j.bmcl.2022.128591_b0185","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1158\/1078-0432.CCR-05-0714","article-title":"The Role of S100A6 in Pancreatic Cancer Development and Its Clinical Implication as a Diagnostic Marker and Therapeutic Target","volume":"11","author":"Ohuchida","year":"2005","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.bmcl.2022.128591_b0190","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/med.21519","article-title":"Protein-protein interactions as antibiotic targets: A medicinal chemistry perspective","volume":"40","author":"Cossar","year":"2020","journal-title":"Med Res Rev."},{"key":"10.1016\/j.bmcl.2022.128591_b0195","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/cmdc.201900643","article-title":"Amino Alcohol Acrylonitriles as Activators of the Aryl Hydrocarbon Receptor Pathway: An Unexpected MTT Phenotypic Screening Outcome","volume":"15","author":"Baker","year":"2020","journal-title":"ChemMedChem."},{"key":"10.1016\/j.bmcl.2022.128591_b0200","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cmdc.202000721","article-title":"Modelling and Phenotypic Screening of NAP-6 and 10-Cl-BBQ, AhR Ligands Displaying Selective Breast Cancer Cytotoxicity in Vitro","volume":"16","author":"Baker","year":"2021","journal-title":"ChemMedChem."},{"key":"10.1016\/j.bmcl.2022.128591_b0205","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/cmdc.201800256","article-title":"Dichlorophenylacrylonitriles as AhR Ligands Displaying Selective Breast Cancer Cytotoxicity in Vitro","volume":"13","author":"Baker","year":"2018","journal-title":"ChemMedChem."},{"key":"10.1016\/j.bmcl.2022.128591_b0210","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.1039\/C5OB00751H","article-title":"1,8-Naphthalimide Derivatives: New Leads against Dynamin I GTPase Activity","volume":"13","author":"Abdel-hamid","year":"2015","journal-title":"Org. Biomol. Chem."}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22000671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22000671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:44:25Z","timestamp":1760773465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22000671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":42,"alternative-id":["S0960894X22000671"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128591","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3,5-Bis(trifluoromethyl)phenylsulfonamides, a novel pancreatic cancer active lead. Investigation of the terminal aromatic moiety","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128591"}}